PL366455A1 - Kwas lipoteichowy z bakterii kwasu mlekowego i jego zastosowanie do modulowania odpowiedzi immunologicznych wywoływanych przez bakterie Gram-ujemne, potencjalnie chorobotwórcze bakterie Gram-dodatnie - Google Patents

Kwas lipoteichowy z bakterii kwasu mlekowego i jego zastosowanie do modulowania odpowiedzi immunologicznych wywoływanych przez bakterie Gram-ujemne, potencjalnie chorobotwórcze bakterie Gram-dodatnie

Info

Publication number: PL366455A1
Authority: PL; Poland
Prior art keywords: bacteria; gram; lactic acid; immune responses; lipoteichoic
Prior art date: 2001-05-23

Application number

PL02366455A

Other languages

English (en)

Inventor

Karine Vidal

Anne Donnet-Hughes

Dominique-Anne Granato

Irene Corthesy-Theulaz

Original Assignee

Societe Des Produits Nestle S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-23

Filing date

2002-04-23

Publication date

2005-02-07

2002-04-23 Application filed by Societe Des Produits Nestle S.A. filed Critical Societe Des Produits Nestle S.A.

2005-02-07 Publication of PL366455A1 publication Critical patent/PL366455A1/pl

Links

JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title abstract 8
241000894006 Bacteria Species 0.000 title abstract 6
239000002253 acid Substances 0.000 title abstract 4
235000014655 lactic acid Nutrition 0.000 title abstract 4
239000004310 lactic acid Substances 0.000 title abstract 4
230000028993 immune response Effects 0.000 title abstract 3
241000192125 Firmicutes Species 0.000 title abstract 2
230000001404 mediated effect Effects 0.000 title abstract 2
230000001717 pathogenic effect Effects 0.000 title abstract 2
239000004480 active ingredient Substances 0.000 abstract 2
208000034309 Bacterial disease carrier Diseases 0.000 abstract 1
210000000988 bone and bone Anatomy 0.000 abstract 1
239000002537 cosmetic Substances 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
210000001508 eye Anatomy 0.000 abstract 1
210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
210000004072 lung Anatomy 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
210000000214 mouth Anatomy 0.000 abstract 1
229940023486 oral product Drugs 0.000 abstract 1
210000003491 skin Anatomy 0.000 abstract 1
239000006228 supernatant Substances 0.000 abstract 1
229940025703 topical product Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Birds (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Immunology (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Tropical Medicine & Parasitology (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)

PL02366455A 2001-05-23 2002-04-23 Kwas lipoteichowy z bakterii kwasu mlekowego i jego zastosowanie do modulowania odpowiedzi immunologicznych wywoływanych przez bakterie Gram-ujemne, potencjalnie chorobotwórcze bakterie Gram-dodatnie PL366455A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP01201958A EP1260227A1 (en)	2001-05-23	2001-05-23	Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria

Publications (1)

Publication Number	Publication Date
PL366455A1 true PL366455A1 (pl)	2005-02-07

Family

ID=8180365

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02366455A PL366455A1 (pl)	2001-05-23	2002-04-23	Kwas lipoteichowy z bakterii kwasu mlekowego i jego zastosowanie do modulowania odpowiedzi immunologicznych wywoływanych przez bakterie Gram-ujemne, potencjalnie chorobotwórcze bakterie Gram-dodatnie

Country Status (21)

Country	Link
US (3)	US20040147010A1 (pl)
EP (2)	EP1260227A1 (pl)
JP (1)	JP4738717B2 (pl)
KR (1)	KR20040018375A (pl)
CN (1)	CN100502888C (pl)
AT (1)	ATE394111T1 (pl)
AU (1)	AU2002338873B8 (pl)
BR (1)	BR0209975A (pl)
CA (1)	CA2449403C (pl)
DE (1)	DE60226436D1 (pl)
DK (1)	DK1395269T3 (pl)
ES (1)	ES2305256T3 (pl)
IN (1)	IN2003DE02242A (pl)
MX (1)	MX260807B (pl)
NO (1)	NO20035187L (pl)
PL (1)	PL366455A1 (pl)
PT (1)	PT1395269E (pl)
RU (1)	RU2320356C2 (pl)
SG (1)	SG101083A1 (pl)
WO (1)	WO2002094296A1 (pl)
ZA (1)	ZA200309821B (pl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2408573A (en) *	2003-11-25	2005-06-01	Univ Leicester	Assay for the interaction of L-Ficolin with lipoteichoic acid
MXPA06006394A (es) *	2003-12-04	2007-01-25	Biofilms Strategies Inc	Metodos y composiciones para prevenir formaciones de biopeliculas, reducir biopeliculas existentes y para reducir poblaciones de bacterias.
US7709032B2 (en)	2003-12-05	2010-05-04	Toyo R&D Inc.	Anti-allergic agent containing both ground lotus and/or extract and lactic acid bacterium
US8877178B2 (en)	2003-12-19	2014-11-04	The Iams Company	Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en)	2003-12-19	2005-07-21	The Procter & Gamble Company	Canine probiotic Bifidobacteria pseudolongum
US7510734B2 (en)	2004-03-04	2009-03-31	E-L Management Corporation	Skin treatment method with Lactobacillus extract
US7862808B2 (en) *	2004-07-01	2011-01-04	Mead Johnson Nutrition Company	Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
JP4726109B2 (ja) *	2005-02-10	2011-07-20	昭和電工株式会社	皮膚外用剤、それを用いる皮膚有害微生物の付着予防方法及び増殖防止方法
US7303745B2 (en) *	2005-04-15	2007-12-04	Bristol-Myers Squibb Company	Method for preventing or treating the development of respiratory allergies
ATE512211T1 (de)	2005-05-31	2011-06-15	Iams Company	Feline probiotische lactobacilli
ES2607988T3 (es)	2005-05-31	2017-04-05	Iams Europe B.V.	Bifidobacterias probióticas felinas
ES2551719T3 (es)	2007-02-01	2015-11-23	Iams Europe B.V.	Procedimiento para disminuir la inflamación y el estrés en un mamífero usando antimetabolitos de glucosa, aguacate o extractos de aguacate
WO2008106763A1 (en) *	2007-03-08	2008-09-12	The Governors Of The University Of Alberta	Bacterial endotoxin for the prevention of metabolic disorders and bacterial infections
US20080299098A1 (en) *	2007-04-24	2008-12-04	Chea-Yun Se	Broad-Spectrum Antibacterial and Antifungal Activity of Lactobacillus Johnsonii D115
JP5225652B2 (ja) *	2007-10-29	2013-07-03	雪印メグミルク株式会社	アディポネクチン分泌促進及び／又は減少抑制剤
US9771199B2 (en) *	2008-07-07	2017-09-26	Mars, Incorporated	Probiotic supplement, process for making, and packaging
EP2140772A1 (en) *	2008-07-03	2010-01-06	Nestec S.A.	Temperature-induced delivery of nutrients by micro-organisms in the gastrointestinal tract
US9232813B2 (en) *	2008-07-07	2016-01-12	The Iams Company	Probiotic supplement, process for making, and packaging
AU2009333388A1 (en) *	2008-12-16	2011-06-30	Nestec S.A.	Compositions and methods for improved oral health
US8784798B2 (en) *	2009-05-11	2014-07-22	Nestec S.A.	Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
US10104903B2 (en)	2009-07-31	2018-10-23	Mars, Incorporated	Animal food and its appearance
JP2013502456A (ja) *	2009-08-26	2013-01-24	アールエヌエーアイエヌシー	リポタイコ酸由来の糖脂質及びこれを含む組成物
WO2012118535A1 (en)	2011-03-01	2012-09-07	Quorum Innovations, Llc	Materials and methods for treating conditions associated with pathogenic biofilm
WO2012116447A1 (en) *	2011-03-03	2012-09-07	The Governors Of The University Of Alberta	Use of bacterial endotoxins and lipoteichoic acids to improve postpartal health and productivity of dairy cows and their newborns
GB201112091D0 (en) *	2011-07-14	2011-08-31	Gt Biolog Ltd	Bacterial strains isolated from pigs
GB201117313D0 (en)	2011-10-07	2011-11-16	Gt Biolog Ltd	Bacterium for use in medicine
US20130089638A1 (en) *	2011-10-11	2013-04-11	Mead Johnson Nutrition Company	Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes
EP2589387A1 (en) *	2011-11-04	2013-05-08	Lunamed AG	Use of a teichoic acid for the treatment of malignant liquor cerebrospinalis in the brain
CN102399733B (zh) *	2011-12-14	2014-07-09	北京大北农科技集团股份有限公司	约氏乳杆菌及其菌剂、应用和预混料
GB201306536D0 (en)	2013-04-10	2013-05-22	Gt Biolog Ltd	Polypeptide and immune modulation
US9399048B2 (en) *	2014-03-05	2016-07-26	Asian Probiotics And Prebiotics Ltd	Lactic acid bacteria and its applications in immunomodulation and anti-inflammation
CN104161775A (zh) *	2014-05-29	2014-11-26	浙江大学宁波理工学院	来自丁酸梭菌的脂磷壁酸在调节水产动物免疫应答中的用途
CN104161776A (zh) *	2014-05-29	2014-11-26	浙江大学宁波理工学院	来自丁酸梭菌的脂磷壁酸及其调节畜禽免疫应答的用途
CN113862175A (zh)	2014-12-23	2021-12-31	4D制药研究有限公司	免疫调控
PL3193901T3 (pl)	2014-12-23	2018-10-31	4D Pharma Research Limited	Polipeptyd pyrynowy i immunomodulacja
AU2016219070B2 (en)	2015-02-13	2020-06-11	Mars, Incorporated	Pet food feeding system
MA41010B1 (fr)	2015-06-15	2020-01-31	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
RS59446B1 (sr)	2015-06-15	2019-11-29	4D Pharma Res Ltd	Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
MA41060B1 (fr)	2015-06-15	2019-11-29	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
MD3206700T2 (ro)	2015-06-15	2019-12-31	4D Pharma Res Ltd	Compoziții conținând tulpini bacteriene
PE20180267A1 (es)	2015-06-15	2018-02-06	4D Pharma Res Ltd	Composiciones que comprenden cepas bacterianas
WO2017085520A1 (en)	2015-11-20	2017-05-26	4D Pharma Research Limited	Compositions comprising bacterial strains
GB201520497D0 (en)	2015-11-20	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
GB201520631D0 (en)	2015-11-23	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
GB201520638D0 (en)	2015-11-23	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
JP6441536B2 (ja)	2016-03-04	2018-12-19	フォーディーファーマピーエルシー４ＤＰｈａｒｍａＰｌｃ	細菌株を含む組成物
GB201612191D0 (en)	2016-07-13	2016-08-24	4D Pharma Plc	Compositions comprising bacterial strains
WO2017173240A1 (en)	2016-03-31	2017-10-05	Gojo Industries, Inc.	Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en)	2016-03-31	2020-12-29	Gojo Industries, Inc.	Sanitizer composition with probiotic/prebiotic active ingredient
CA3018768C (en)	2016-03-31	2024-03-26	Gojo Industries, Inc.	Antimicrobial peptide stimulating sanitizing composition
TW201821093A (zh)	2016-07-13	2018-06-16	英商４Ｄ製藥有限公司	包含細菌菌株之組合物
CN106236826A (zh) *	2016-08-12	2016-12-21	福建万亿店中店电子商务有限责任公司	一种用于阴道疾病辅助治疗的乳酸菌磷壁酸凝胶
JP2020500860A (ja)	2016-11-23	2020-01-16	ゴジョ・インダストリーズ・インコーポレイテッド	プロバイオティック／プレバイオティックな有効成分を含む消毒薬組成物
GB201621123D0 (en)	2016-12-12	2017-01-25	4D Pharma Plc	Compositions comprising bacterial strains
HUE054164T2 (hu)	2017-05-22	2021-08-30	4D Pharma Res Ltd	Baktériumtörzseket tartalmazó készítmények
WO2018215782A1 (en)	2017-05-24	2018-11-29	4D Pharma Research Limited	Compositions comprising bacterial strain
KR102205829B1 (ko) *	2017-06-14	2021-01-21	기초과학연구원	신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체
SMT202000695T1 (it)	2017-06-14	2021-01-05	4D Pharma Res Limited	Composizioni comprendenti ceppi batterici
LT3600363T (lt)	2017-06-14	2021-02-10	4D Pharma Research Limited	Kompozicijos, apimančios bakterijų kamienus
MA49010B1 (fr)	2017-06-14	2020-11-30	4D Pharma Res Ltd	Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations
US11197917B2 (en)	2017-12-01	2021-12-14	ByHeart, Inc.	Formulations for nutritional support in subjects in need thereof
CN111053789A (zh) *	2019-11-26	2020-04-24	湖南营养树生物科技有限公司	调节免疫系统的方法和组合物
EP4081225A1 (en) *	2019-12-27	2022-11-02	Biopolis, S.L.	Uses of lipoteichoic acid from bifidobacteria
KR102325947B1 (ko)	2020-02-05	2021-11-15	주식회사 에이치이엠파마	신규한 락토바실러스 사케이 hem224 균주, 및 상기 균주 또는 이의 배양물을 포함하는 염증 또는 천식의 치료용 조성물
EP4152948A4 (en) *	2020-06-26	2024-08-07	Zivo Bioscience, Inc.	IMMUNE PRIMING TO ACCELERATE/ENHANCE THE IMMUNE RESPONSE BY ADMINISTRATION OF A NATURAL IMMUNE MODULATOR
JP2023179810A (ja) *	2020-11-13	2023-12-20	味の素株式会社	ラクトコッカス・ラクチス、ラクトバチルス属に属する微生物、又はこれらの混合微生物を含有する生菌剤及びその製造方法
JP7717383B2 (ja) *	2022-03-03	2025-08-04	株式会社アルソア慧央グループ	腸管免疫賦活剤、ＩｇＡ産生促進剤及び遺伝子発現促進剤
CN115068510A (zh) *	2022-05-24	2022-09-20	宁波大学	一种乳杆菌脂磷壁酸的提取方法及其抗炎活性应用
CN117099871B (zh) *	2023-08-07	2025-12-26	集美大学	一种来自枯草芽孢杆菌的脂磷壁酸及其维持牛蛙肠道健康的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6048929A (ja) *	1983-08-26	1985-03-16	Chugai Pharmaceut Co Ltd	抗腫瘍剤
JPS6048928A (ja) *	1983-08-26	1985-03-16	Chugai Pharmaceut Co Ltd	Ｔνｆ誘起剤
US4678773A (en)	1983-08-26	1987-07-07	Chugai Seiyaku Kabushiki Kaisha	Antitumor agent
JPS61275217A (ja) *	1985-05-29	1986-12-05	Yakult Honsha Co Ltd	グラム陰性桿菌感染症防御剤
US5804179A (en) *	1985-12-31	1998-09-08	Research Corporation Technologies, Inc.	Lactobacillus compositions and methods for treating urinary tract infections
DE3817762A1 (de) *	1988-05-26	1989-11-30	Sanum Kehlbeck Gmbh & Co Kg	Immunstimulierendes mittel aus propionibakterien sowie verfahren zur herstellung desselben
ES2111625T3 (es) *	1992-07-06	1998-03-16	Nestle Sa	Agente antigastritis.
AU6362594A (en) *	1993-03-10	1994-09-26	Miles Inc.	Hyaluronic acid used as a cancer treatment
US6180100B1 (en) *	1994-09-30	2001-01-30	Urex Biotech., Inc.	Lactobacillus compositions and methods for treating urinary tract infections
JP3489930B2 (ja) *	1996-03-08	2004-01-26	株式会社ヤクルト本社	がん予防食品
EP0818529B1 (fr) *	1996-07-09	2005-06-22	Societe Des Produits Nestle S.A.	Procédé de séchage par pulvérisation
ATE206873T1 (de) *	1997-01-09	2001-11-15	Nestle Sa	Probiotik enthaltendes getreideprodukt
US5998482A (en) *	1997-11-10	1999-12-07	David; Sunil A.	Use of synthetic polycationic amphiphilic substances with fatty acid or hydrocarbon substituents as anti-sepsis agents
JP3046303B1 (ja) *	1999-06-24	2000-05-29	明治乳業株式会社	Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性飲食品
DE19963420A1 (de) *	1999-12-28	2001-07-12	Sebo Gmbh	Gewinnung von biologischen Komponenten aus Körperflüssigkeiten

2001
- 2001-05-23 EP EP01201958A patent/EP1260227A1/en not_active Withdrawn
2002
- 2002-04-23 ES ES02742909T patent/ES2305256T3/es not_active Expired - Lifetime
- 2002-04-23 RU RU2003136828/15A patent/RU2320356C2/ru not_active IP Right Cessation
- 2002-04-23 DK DK02742909T patent/DK1395269T3/da active
- 2002-04-23 MX MXPA03010598 patent/MX260807B/es active IP Right Grant
- 2002-04-23 EP EP02742909A patent/EP1395269B1/en not_active Expired - Lifetime
- 2002-04-23 AU AU2002338873A patent/AU2002338873B8/en not_active Ceased
- 2002-04-23 KR KR20037015185A patent/KR20040018375A/ko not_active Ceased
- 2002-04-23 CA CA2449403A patent/CA2449403C/en not_active Expired - Fee Related
- 2002-04-23 SG SG200306895A patent/SG101083A1/en unknown
- 2002-04-23 US US10/478,079 patent/US20040147010A1/en not_active Abandoned
- 2002-04-23 CN CNB02810479XA patent/CN100502888C/zh not_active Expired - Fee Related
- 2002-04-23 WO PCT/EP2002/004436 patent/WO2002094296A1/en not_active Ceased
- 2002-04-23 DE DE60226436T patent/DE60226436D1/de not_active Expired - Lifetime
- 2002-04-23 PT PT02742909T patent/PT1395269E/pt unknown
- 2002-04-23 JP JP2002591013A patent/JP4738717B2/ja not_active Expired - Fee Related
- 2002-04-23 BR BR0209975-6A patent/BR0209975A/pt not_active Application Discontinuation
- 2002-04-23 PL PL02366455A patent/PL366455A1/pl not_active IP Right Cessation
- 2002-04-23 AT AT02742909T patent/ATE394111T1/de active
2003
- 2003-11-21 NO NO20035187A patent/NO20035187L/no not_active Application Discontinuation
- 2003-12-18 ZA ZA200309821A patent/ZA200309821B/xx unknown
- 2003-12-23 IN IN2242DE2003 patent/IN2003DE02242A/xx unknown
2008
- 2008-10-07 US US12/246,991 patent/US8329190B2/en not_active Expired - Fee Related
2013
- 2013-08-15 US US13/967,936 patent/US20140056927A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2449403C (en)	2011-11-15
US20090142375A1 (en)	2009-06-04
WO2002094296A1 (en)	2002-11-28
CN1525863A (zh)	2004-09-01
CN100502888C (zh)	2009-06-24
SG101083A1 (en)	2006-02-28
AU2002338873B2 (en)	2008-04-10
EP1395269B1 (en)	2008-05-07
ZA200309821B (en)	2005-03-18
ATE394111T1 (de)	2008-05-15
AU2002338873B8 (en)	2008-05-08
EP1395269A1 (en)	2004-03-10
PT1395269E (pt)	2008-06-16
US8329190B2 (en)	2012-12-11
RU2320356C2 (ru)	2008-03-27
US20040147010A1 (en)	2004-07-29
RU2003136828A (ru)	2005-03-10
NO20035187D0 (no)	2003-11-21
DK1395269T3 (da)	2008-08-04
ES2305256T3 (es)	2008-11-01
MX260807B (es)	2008-09-25
BR0209975A (pt)	2004-04-06
CA2449403A1 (en)	2002-11-28
AU2002338873A1 (en)	2002-12-03
MXPA03010598A (es)	2004-03-09
IN2003DE02242A (en)	2006-01-20
EP1260227A1 (en)	2002-11-27
JP4738717B2 (ja)	2011-08-03
US20140056927A1 (en)	2014-02-27
DE60226436D1 (de)	2008-06-19
NO20035187L (no)	2004-01-05
JP2005500267A (ja)	2005-01-06
KR20040018375A (ko)	2004-03-03

Legal Events

Date	Code	Title	Description
2010-11-30	VOID	Decisions declaring the decisions on the grant of the patent lapsed

Publication	Publication Date	Title
ZA200309821B (en)	2005-03-18	Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by Gram-negative bacteria, potential pathogenic gram-positive bacteria.
Sekhar et al.	2014	Topical application/formulation of probiotics: will it be a novel treatment approach for diabetic foot ulcer?
CA2688736C (en)	2017-07-04	Novel compositions containing lysozyme and c-1/c-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology
EA200200059A1 (ru)	2003-02-27	Комбинация молочнокислых бактерий и ее применение для профилактики и/или лечения инфекций и воспалительных состояний
DE60143356D1 (de)	2010-12-09	Ernährungszusammensetzung
BR0113861A (pt)	2004-01-27	Derivados de ácidos 3-(heteroaril acetamido)-2-oxo-azetidina-1-sulfÈnicos como agentes antibacterianos
MY159377A (en)	2016-12-30	Aqueous suspensions of ciclesonide for nebulisation
Coenye et al.	2008	Biofilms in skin infections: Propionibacterium acnes and acne vulgaris
ATE289805T1 (de)	2005-03-15	Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
BRPI0413509A (pt)	2006-10-10	uso de antibióticos de quinolona
BR0116653A (pt)	2004-02-17	Medicamento contendo uma poliamina como substância ativa
GICHKI et al.	2012	HEALING EFFECTS OF NATURAL HONEY ON ORAL MINOR APTHOUS ULCERS AMONG DENTAL PATIENTS IN QUETTA.
Belal	2021	Relevance of bacterial normal flora in antimicrobial resistance and how to overcome this resistance
DE602004017586D1 (de)	2008-12-18	Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus
GB0114672D0 (en)	2001-08-08	Pharmaceutical formulations and methods of medical treatment
Pereira et al.	2017	Biofilm and inhibition of Bacterial Growth in Caries Prevention
WO2002074287A3 (en)	2003-05-01	Antibacterial compositions containing of oxapenem-3-carboxylic acids and antibiotics
CN111479569A (zh)	2020-07-31	氯唑西林抑制/预防生物膜形成的用途
MX2025007361A (es)	2025-07-01	Composicion y productos que comprenden un antibiotico y un glucocorticoide para tratar la mastitis
Notari et al.	1989	Ciprofloxacin: a study of usage in pedal infections with case reports
Hassan et al.	2012	The Increasing importance of Normal Flora Commensals in Health or Potentially Pathogens for Disease
WO2003022881A3 (de)	2003-08-21	Phänotyp bestimmende virulenzgene von pseudomonas aeruginosa zur kolonisation und persistenz in mensch, tier und pflanze, verwendungen der gene und zugehörigen proteine
BRPI0504979B8 (pt)	2021-05-25	composições farmacêuticas antibacterianas